ACTH 1-17 effects in acute myeloid leukemia.

Abstract

We conducted a double blind randomized clinical study with 100 micrograms i.v. ACTH 1-17 versus placebo in 40 consecutive acute myelocytic leukemia patients (AML). The same regimen 3 + 7 schedule, employing daunorubicin (DNR) associated with cytosine-arabinoside (ARA-C), was applied as remission induction therapy to all patients. Prednisone therapy was performed as necessary. Twenty patients, receiving ACTH 1-17, were compared with 20 other patients receiving placebo in regard to remission rate, hemorrhagic and infective complications, remission duration and survival. No significant difference was observed between the 2 groups for all parameters taken into consideration. The two year actuarial curves of remission duration and survival showed a trend in favour of the ACTH 1-17 group. It needs a longer follow-up to evaluate if ACTH 1-17 will represent an effective adjuvant of the induction chemotherapy for the long-term control of the acute myelocytic leukemia.

• Authors: W Arcese, C Nervi, G Avvisati, F Mandelli
• Journal: La Ricerca in clinica e in laboratorio (Ric Clin Lab) 1984 Apr-Jun Vol. 14 Issue 2 Pg. 199-203 ISSN: 0390-5748 [Print] Italy
• PMID: 6091244 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Peptide Fragments
• Cytarabine
• Adrenocorticotropic Hormone
• ACTH (1-17)
• Daunorubicin

Topics

• Adolescent
• Adrenocorticotropic Hormone (therapeutic use)
• Adult
• Cytarabine (administration & dosage)
• Daunorubicin (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Leukemia, Myeloid, Acute (drug therapy)
• Male
• Middle Aged
• Peptide Fragments (therapeutic use)